Press Releases 2013

PsychoGenics Obtains an Exclusive License to the APP/PS1 Transgenic Mouse Model of Alzheimer’s Disease

August 21, 2013 – Tarrytown, New York. - PsychoGenics announced today that it has obtained an exclusive license from the University of South Florida to its APP/PS1 double transgenic mice (US Patent No. 5,898,094), co-expressing the M146L presenilin 1(PS1) mutation and the double mutations at K670N/M671L (Swedish mutation) in the amyloid precursor protein (APP). Read More.

PsychoGenics and Sunovion Pharmaceuticals Inc. Expand their Drug Discovery Partnership

June 17, 2013 – Tarrytown, New York. - PsychoGenics Inc. and Sunovion Pharmaceuticals Inc. announced that they have expanded the scope of their CNS drug discovery partnership and extended the agreement for another two years. Read More.


  • PsychoGenics
  • 215 College Road, Paramus, NJ 07652
  • Tel: (914) 406-8000
  • Fax: (914) 406-8090